A5036367526- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- vaccines and immunoinformatics approaches
- T-cell and B-cell Immunology
- Immune Response and Inflammation
- Hepatitis C virus research
- Animal Virus Infections Studies
- Immune cells in cancer
- Peptidase Inhibition and Analysis
- Protein Degradation and Inhibitors
- Cancer Mechanisms and Therapy
- Phagocytosis and Immune Regulation
- Multiple Myeloma Research and Treatments
- Histone Deacetylase Inhibitors Research
- Hepatitis B Virus Studies
- SARS-CoV-2 and COVID-19 Research
- Chemokine receptors and signaling
- Virus-based gene therapy research
- Advanced biosensing and bioanalysis techniques
- Ferroptosis and cancer prognosis
- IL-33, ST2, and ILC Pathways
- interferon and immune responses
Navarre Institute of Health Research
2015-2025
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2020-2025
Clinica Universidad de Navarra
2024-2025
Universidad de Navarra
2015-2024
Centro de Investigación Biomédica en Red
2022-2024
Complejo Hospitalario de Navarra
2019
Gene Therapy Laboratory
2007-2013
Chartered Institute of Management Accountants
2013
PDL1 blockade produces remarkable clinical responses, thought to occur by T cell reactivation through prevention of PDL1-PD1 inhibitory interactions. Here, we find that cell-intrinsic signaling protects cancer cells from interferon (IFN) cytotoxicity and accelerates tumor progression. inhibited IFN signal transduction a conserved class sequence motifs mediate crosstalk with signaling. Abrogation expression or antibody-mediated strongly sensitized STAT3/caspase-7-dependent pathway. Moreover,...
Abstract The historical lack of preclinical models reflecting the genetic heterogeneity multiple myeloma (MM) hampers advance therapeutic discoveries. To circumvent this limitation, we screened mice engineered to carry eight MM lesions (NF-κB, KRAS, MYC, TP53, BCL2, cyclin D1, MMSET/NSD2 and c-MAF) combinatorially activated in B lymphocytes following T cell-driven immunization. Fifteen genetically diverse developed bone marrow (BM) tumors fulfilling pathogenesis. Integrative analyses ∼500...
Abstract Immunosuppressive activity of regulatory T cells (Treg) may contribute to the progression cancer or infectious diseases by preventing induction specific immune responses. Using a phage-displayed random peptide library, we identified 15-mer synthetic peptide, P60, able bind forkhead/winged helix transcription factor 3 (FOXP3), required for development and function Treg. P60 enters cells, inhibits FOXP3 nuclear translocation, reduces its ability suppress factors NF-κB NFAT. In vitro,...
Abstract Vaccination strategies based on the in vivo targeting of Ags to dendritic cells (DCs) are needed improve induction specific T cell immunity against tumors and infectious agents. In this study, we have used a recombinant protein encompassing extra domain A from fibronectin (EDA), an endogenous ligand for TLR4, deliver TLR4-expressing DC. The purified EDA was shown bind HEK293 activate TLR4 signaling pathway. also stimulated production by DC proinflammatory cytokines such as IL-12 or...
Low antigen expression and an absence of coimmunostimulatory signals may be partly responsible for the low immunogenicity many tumors. It possible to overcome this situation by defining a combination adjuvants antigens that can activate high-avidity antitumor response. Using poorly immunogenic B16-OVA melanoma cells as tumor model, we tested different combinations treat established In exogenous antigens, repeated administration TLR7 ligand Imiquimod together with anti-CD40 agonistic...
Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) blockade therapy is able to induce long-lasting antitumor responses in a fraction of cancer patients. Nonetheless, there still room for improvement the quest new therapeutic combinations. ICOS costimulation has been underscored as possible target include with CTLA-4 blocking treatment. Herein, we describe an agonistic aptamer that potentiates cell activation and induces stronger when locally injected at tumor site combination anti-CTLA-4...
Background Neoantigens, new immunogenic sequences arising from tumor mutations, have been associated with response to immunotherapy and are considered potential targets for vaccination. Hepatocellular carcinoma (HCC) is a moderately mutated tumor, where the neoantigen repertoire has not investigated. Our aim was analyze whether tumors in HCC patients contain neoantigens suitable future use therapeutic Methods Whole-exome sequencing RNAseq were performed cohort of fourteen submitted surgery...
Immunotherapy with immune checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC) patients only achieves response rates of 25%–30%, indicating the necessity new therapies for non-responder patients. Since myeloid-related suppressive factors are associated poor responses to ICI a subgroup HCC patients, modulation these targets may improve rates. Our aim was characterize expression efferocytosis receptor MERTK and analyze its potential as therapeutic target. In expressed by myeloid cells...
<p>Supplementary Figure 4</p>
<p>Supplementary Figure 12</p>
<p>Supplementary Figure 10</p>
<p>Supplementary Figure 14</p>
<p>Supplementary Figure 5</p>
<p>Supplementary Figure 13</p>
<p>Supplementary Figure 15</p>
<p>Supplementary Figure 1</p>
<p>Supplementary Figure 11</p>
<div>Abstract<p>The precise mechanisms by which the complement system contributes to establishment of an immunosuppressive tumor microenvironment and promotes progression remain unclear. In this study, we investigated expression function C5a receptor 1 (C5aR1) in human mouse cancer-associated dendritic cells (DC). First, observed overexpression C5aR1 tumor-infiltrating DCs, compared with DCs from blood or spleen. was restricted type 2 conventional monocyte-derived displayed a...
<p>Supplementary Figure 6</p>
<p>Supplementary Figure 2</p>
<p>Supplementary Figure 8</p>
<p>Supplementary Figure 3</p>
<p>Supplementary Figure 9</p>